Objectives To develop a preliminary composite psoriatic disease activity index (CPDAI) for psoriasis and psoriatic arthritis.
Methods Five domains were assessed and specific instruments were employed for each domain to determine the extent of domain involvement and the effect of that involvement on quality of life/function. Disease activity for each domain was then graded from 0 to 3 giving a CPDAI range of 0–15. Patient and physician global disease activity measures were also recorded and an independent physician was asked to indicate if treatment change was required. Bivariate correlation analysis was performed. Factor, tree analysis and standardised response means were also calculated.
Results Significant correlation was seen between CPDAI and both patient (r=0.834) and physician (r=0.825) global disease activity assessments (p=0.01). Tree analysis revealed that 96.3% of patients had their treatment changed when CPDAI values were greater than 6; no patient had their treatment changed when CPDAI values were less than 5.
Conclusion CPDAI correlates well with patient and physician global disease activity assessments and is an effective tool that clearly distinguishes those who require a treatment change from those who do not.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding AM's University College Dublin Newman Fellowship was supported by an unrestricted educational grant from Abbott (Ireland) Ltd. LCC is supported by the Arthritis Research Campaign as an ARC Clinical Research Fellow.
Competing interests None.
Ethics approval This study was conducted with the approval of the ethics committees of St Vincents University Hospital Dublin and the University of Leeds.
Provenance and peer review Not commissioned; externally peer reviewed.